Noviga Research is a Swedish Pharma/Biotech Company focused on the development of novel medicines for the treatment of diseases with high unmet medical need, such as cancer. The company is based at the Biovation Park (former AstraZeneca R&D facility) in Södertälje, Sweden. Noviga develops small-molecule patented drugs that can extend patient life, our lead anti-cancer compound NOV202 is close to entering GLP-tox and safety studies, followed by a Phase Ib/IIa clinical trial in patients with relapsing and/or treatment refractory cancer.
Overall, approximately 70% of patients diagnosed with ovarian epithelial cancer will relapse after first-line platinum- and taxane-based chemotherapy and thus there is a large unmet medical need for novel and safe second line therapies. Furthermore, a significant proportion of breast and lung cancer patients, comprising around 20% of all cancer patients, also develop resistance to taxane-based chemotherapy, underlining the critical need for new therapeutic approaches. Preclinical studies have shown that Noviga’s lead compound, NOV202, could be of clinical benefit to these specific patient populations, which warrant the clinical development of this compound.
Copyright © Noviga Research AB 2014
Innovative Research to Fight Cancer
The Noviga Commitment